FAQ
CALMA
IGC Pharma holds a diverse portfolio of granted and pending patents focused on innovative small molecules and pharmaceutical compositions.
These intellectual properties aim to address unmet medical needs in Alzheimer’s Disease, central nervous system disorders, epilepsy, cancer, eating disorders, and more
Safe, well-tolerated and may reduce agitation and
caregiver distress in Alzheimer’s disease.
Reduces diagnostic delays in underserved areas with limited equipment.
Reveals socio-economic and lifestyle combinations that impact Alzheimer’s progression.
Supports identification of at-risk patients and helps inform public health policy.
Reveals socio-economic and lifestyle combinations that impact Alzheimer’s progression.
Supports identification of at-risk patients and helps inform public health policy.
Reduces diagnostic delays in underserved areas with limited equipment.
Supports identification of at-risk patients and helps inform public health policy.
Reveals socio-economic and lifestyle combinations that impact Alzheimer’s progression.
Reduces diagnostic delays in underserved areas with limited equipment.
Reveals socio-economic and lifestyle combinations that impact Alzheimer’s progression.